Literature DB >> 9047383

RET alternate splicing influences the interaction of activated RET with the SH2 and PTB domains of Shc, and the SH2 domain of Grb2.

M J Lorenzo1, G D Gish, C Houghton, T J Stonehouse, T Pawson, B A Ponder, D P Smith.   

Abstract

Activating germline mutations of the RET receptor tyrosine kinase are found in the majority of cases of inherited cancer syndrome MEN 2, and inactivating mutations in some cases of dominantly inherited Hirschsprung disease. Using RET activated by a MEN 2 mutation, we show that both the SH2 and PTB domains of the adaptor protein Shc interact with RET, and we identify the PTB domain interaction site. Interaction with both the SH2 and PTB domains of Shc contributes to the transcriptional activation of a serum response element. RET alternate splicing affects the strength of interaction with both the Shc SH2 and PTB domains. In addition, a splice isoform-specific HSCR missense mutation, which does not inactivate the RET kinase activity, decreases the strength of the PTB domain interaction and the level of RET-dependent Shc phosphorylation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9047383     DOI: 10.1038/sj.onc.1200894

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  24 in total

Review 1.  Neurotrophic factors and their receptors in axonal regeneration and functional recovery after peripheral nerve injury.

Authors:  J Gordon Boyd; Tessa Gordon
Journal:  Mol Neurobiol       Date:  2003-06       Impact factor: 5.590

2.  Low RET mutation frequency and polymorphism analysis of the RET and EDNRB genes in patients with Hirschsprung disease in Taiwan.

Authors:  Trang-Tiau Wu; Tsui-Wei Tsai; Chao-Ta Chu; Zen-Fung Lee; Chuan-Mao Hung; Ching-Chyuan Su; Shuan-Yow Li; Mingli Hsieh; Chuan Li
Journal:  J Hum Genet       Date:  2005-04-15       Impact factor: 3.172

Review 3.  Pheochromocytoma-associated syndromes: genes, proteins and functions of RET, VHL and SDHx.

Authors:  O Gimm
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

4.  Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade.

Authors:  R M Melillo; M Santoro; S H Ong; M Billaud; A Fusco; Y R Hadari; J Schlessinger; I Lax
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

5.  Internalization of glial cell-derived neurotrophic factor receptor GFR alpha 1 in the absence of the ret tyrosine kinase coreceptor.

Authors:  P Vieira; J Thomas-Crusells; A Vieira
Journal:  Cell Mol Neurobiol       Date:  2003-02       Impact factor: 5.046

6.  Differential activities of the RET tyrosine kinase receptor isoforms during mammalian embryogenesis.

Authors:  E de Graaff; S Srinivas; C Kilkenny; V D'Agati; B S Mankoo; F Costantini; V Pachnis
Journal:  Genes Dev       Date:  2001-09-15       Impact factor: 11.361

7.  The RET proto-oncogene induces apoptosis: a novel mechanism for Hirschsprung disease.

Authors:  M C Bordeaux; C Forcet; L Granger; V Corset; C Bidaud; M Billaud; D E Bredesen; P Edery; P Mehlen
Journal:  EMBO J       Date:  2000-08-01       Impact factor: 11.598

8.  Critical and distinct roles for key RET tyrosine docking sites in renal development.

Authors:  Sanjay Jain; Mario Encinas; Eugene M Johnson; Jeffrey Milbrandt
Journal:  Genes Dev       Date:  2006-02-01       Impact factor: 11.361

9.  A targeting mutation of tyrosine 1062 in Ret causes a marked decrease of enteric neurons and renal hypoplasia.

Authors:  Mayumi Jijiwa; Toshifumi Fukuda; Kumi Kawai; Akari Nakamura; Kei Kurokawa; Yoshiki Murakumo; Masatoshi Ichihara; Masahide Takahashi
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

10.  Gdnf upregulates c-Fos transcription via the Ras/Erk1/2 pathway to promote mouse spermatogonial stem cell proliferation.

Authors:  Zuping He; Jiji Jiang; Maria Kokkinaki; Nady Golestaneh; Marie-Claude Hofmann; Martin Dym
Journal:  Stem Cells       Date:  2007-10-25       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.